Neal D. Shore

Urology

823 82nd Pkwy
Myrtle Beach, SC 29572

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 509 publications

Commentary on "matching-adjusted indirect comparison of enzalutamide versus darolutamide doublet in mHSPC".

Commentary on "matching-adjusted indirect comparison of enzalutamide versus darolutamide doublet in mHSPC".

Journal: Future oncology (London, England)

Published: August 08, 2026

Enzalutamide Monotherapy for the Treatment of Prostate Cancer with High-Risk Biochemical Recurrence: EMBARK Secondary End Points: Erratum.

Enzalutamide Monotherapy for the Treatment of Prostate Cancer with High-Risk Biochemical Recurrence: EMBARK Secondary End Points: Erratum.

Journal: The Journal of urology

Published: July 09, 2026

Treatment of High-Risk Biochemically Recurrent Prostate Cancer with Enzalutamide in Combination with Leuprolide: Secondary End Points from the EMBARK Trial: Erratum.

Treatment of High-Risk Biochemically Recurrent Prostate Cancer with Enzalutamide in Combination with Leuprolide: Secondary End Points from the EMBARK Trial: Erratum.

Journal: The Journal of urology

Published: July 09, 2026

Enzalutamide in biochemically recurrent prostate cancer: clinical implications from EMBARK for real-world practice.

Enzalutamide in biochemically recurrent prostate cancer: clinical implications from EMBARK for real-world practice.

Journal: Future oncology (London, England)

Published: July 09, 2026

How enzalutamide affects sex life and how taking a break from treatment affects quality of life: a plain language summary of results from the EMBARK study in people with hormone-sensitive prostate cancer and high-risk biochemical recurrence.

How enzalutamide affects sex life and how taking a break from treatment affects quality of life: a plain language summary of results from the EMBARK study in people with hormone-sensitive prostate cancer and high-risk biochemical recurrence.

Journal: Future oncology (London, England)

Published: July 06, 2026

Correspondence: persistence, progression, and PSA: what exactly does DEAR-EXT compare? Yanping Zhu, Xiaohui Wang, Yang Zhang, Shuangwu Lv.

Correspondence: persistence, progression, and PSA: what exactly does DEAR-EXT compare? Yanping Zhu, Xiaohui Wang, Yang Zhang, Shuangwu Lv.

Journal: Prostate cancer and prostatic diseases

Published: June 19, 2026

Water Vapor Therapy for the Management of Prostate Cancer: The VAPOR 2 Study Initial Results of Ablative Efficacy and Toxicity.

Water Vapor Therapy for the Management of Prostate Cancer: The VAPOR 2 Study Initial Results of Ablative Efficacy and Toxicity.

Journal: The Journal of urology

Published: June 10, 2026

A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide with placebo plus enzalutamide for patients with advanced prostate cancer.

A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide with placebo plus enzalutamide for patients with advanced prostate cancer.

Journal: Future oncology (London, England)

Published: June 09, 2026

A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer and changes in specific DNA repair genes.

A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer and changes in specific DNA repair genes.

Journal: Future oncology (London, England)

Published: June 04, 2026

Perioperative Apalutamide in High-Risk Localized Prostate Cancer.

Perioperative Apalutamide in High-Risk Localized Prostate Cancer.

Journal: The New England journal of medicine

Published: June 01, 2026

PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer.

PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer.

Journal: The New England journal of medicine

Published: June 01, 2026

Sasanlimab taken together with Bacillus Calmette-Guérin (BCG) compared with BCG alone in people with high-risk non-muscle invasive bladder cancer: a plain language summary.

Sasanlimab taken together with Bacillus Calmette-Guérin (BCG) compared with BCG alone in people with high-risk non-muscle invasive bladder cancer: a plain language summary.

Journal: Future oncology (London, England)

Published: May 24, 2026

Showing 1-12 of 509

Last Updated: 09/26/2026